HC Wainwright Has Bullish Estimate for ZNTL Q1 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued on Wednesday, January 29th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.41) per share for the quarter, up from their previous forecast of ($0.65). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.42) EPS.

A number of other equities research analysts also recently weighed in on ZNTL. UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Wedbush reiterated a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Finally, Guggenheim reduced their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL traded up $0.02 during mid-day trading on Monday, reaching $2.16. The company had a trading volume of 3,278,452 shares, compared to its average volume of 2,950,098. The stock has a market capitalization of $153.92 million, a PE ratio of -0.87 and a beta of 1.82. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $18.07. The stock's 50 day moving average is $2.81 and its 200-day moving average is $3.21.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36.

Insider Buying and Selling

In related news, Director Jan Skvarka acquired 60,000 shares of the stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the purchase, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.60% of the company's stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Verition Fund Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company's stock worth $5,536,000 after purchasing an additional 951,500 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company's stock worth $2,240,000 after acquiring an additional 353,384 shares during the last quarter. Primecap Management Co. CA increased its position in Zentalis Pharmaceuticals by 21.6% in the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company's stock valued at $5,513,000 after acquiring an additional 265,690 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company's stock worth $843,000 after purchasing an additional 127,868 shares in the last quarter. Finally, Squarepoint Ops LLC grew its stake in shares of Zentalis Pharmaceuticals by 543.8% during the second quarter. Squarepoint Ops LLC now owns 148,755 shares of the company's stock valued at $608,000 after purchasing an additional 125,649 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.